



9th EUROPEAN
CONFERENCE on
INFECTIONS in
LEUKAEMIA

COVID-19 vaccines



► **IN-PERSON CONFERENCE**
From September
15th to 17th 2022

Final
slide set

Specific guidelines for patients with LPD or AL

Even patients in whom the expected response rates to vaccine are low or very low, (eg. those receiving anti-CD20 Abs, or within the 6-12 months following the last dose; with severe hypogammaglobulinemia (< 4g/L), severe lymphopenia (<500/ μ L), BCMA targeted bispecific therapy (Belantamab-mafodotin), or starting an induction chemotherapy for AL), may still benefit from vaccination **Blu**.

However, these patients should be assessed for vaccine response one month after each vaccine dose (from dose 2) in order to assess their response, and discuss the use of pre-exposure MoAbs or other preventative measures



► IN-PERSON CONFERENCE
2022